FDA Accepts Supplement for Trodelvy (Sacituzumab Govitecan-Hziy)
The FDA has accepted a supplemental application for Trodelvy, indicating ongoing development and potential label expansion.
Asset / Drug
Drug and asset intelligence for Immunomedics with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Antibody-Drug Conjugate
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.